Publication date: Sep 05, 2019
Results for Glatiramer Acetate (GA) Depot 3 year analysis in RRMS, GA Depot safety results in RRMS and PPMS, and novel anti-BMP for remyelination will be presented ECTRIMS 2019 to be held in Helsinki, Sweden on September 11-13 NESS ZIONA, Israel, Sept. 04, 2019 (GLOBE NEWSWIRE) — Mapi Pharma Ltd. , a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative solutions for neurological indications, announced today that the company will present recent advancements in its pipeline for treating MS at the leading MS conference, ECTRIMS 2019, which is being held in Helsinki, Sweden on September 11-13, 2019.
Ehud Marom, Chairman and Chief Executive Officer of Mapi, said, “Mapi is working to be the leading MS Company with a long acting GA Depot product for Relapsing Remitting Multiple Sclerosis (RRMS), a unique product for Primary Progressive Multiple Sclerosis (PPMS), a combination treatment of a Depot treatment and stem cells for Secondary Progressive Multiple Sclerosis (SPMS) and a novel treatment anti-BMP remyelination agent for MS. ” “We recently initiated the pivotal Phase III study of GA Depot for treating RRMS patients.
The continued strong results of GA Depot for both RRMS and PPMS demonstrate the product’s safety, tolerability, and efficacy in MS patients.
Mapi’s focus on MS encompasses several technologies ranging from oral dosage forms, for which the company has successfully launched a generic form of Fingolimod (GilenyaTM) for RRMS, to long acting Depot injections, New Chemical Entities (NCE) for remyelination, as well as combinations with stem cells.
|disease||DOID||Secondary Progressive Multiple Sclerosis|
|disease||MESH||Primary Progressive Multiple Sclerosis|
|disease||MESH||Relapsing Remitting Multiple Sclerosis|
- Novartis ofatumumab demonstrates superiority versus Aubagio in two head-to-head Phase III multiple sclerosis studies
- Gilenya, Aubagio, Tysabri, Tecfidera Dominate MS Therapy Switches in Europe, Spherix Survey Finds
- Are Your MS Disease-modifying Treatments Old School or New School?
- Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS